Vactosertib and Durvalumab in Gastric Cancer

Sponsor
Hark Kyun Kim
Study ID
NCT04893252
Phase
PHASE2
Status
Unknown

Conditions

  • Stomach Neoplasm

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This trial will test the efficacy and safety of durvalumab in combination with vactosertib in patients with metastatic gastric cancers who failed ≥ 2 lines of chemotherapy

Key Dates

Start date
Jun 1, 2021
Status verified
Nov 2022
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023

Study Design

Enrollment
55 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: vactosertib in combination with durvalumab
    single arm study

Primary Outcome Measure

Objective response rate [ Time Frame: Every 8 weeks from the date of the first dose until the date of progression, assessed up to 1 year ]

Central Contacts